vTv Therapeutics Inc. announced that it has entered into a securities purchase agreement with Martin Edelman, Samsara BioCapital, LLC, JDRF T1D Fund and certain institutional accredited investors pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement to issue 464,377 class A shares at an issue price of $11.81 per share for the gross proceeds of $5,484,292.37 and pre-funded warrants to purchase up to an aggregate of 3,853,997 shares of Common Stock at an issue price of $11.80 per Pre-Funded Warrant for the gross proceeds of $45,477,164.6; aggregate gross proceeds of $50,961,456.97 on February 27, 2024. The Private Placement closed on February 27, 2024. The Company received aggregate gross proceeds from the Private Placement of approximately $51,000,000, before deducting offering expenses payable by the Company. The Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire.

On March 7, 2024, the company announced that it has raised $50,961,457 in funding pursuant to exemption provided under Regulation D. The transaction included participation from 4 investors.